Why the Imugene (ASX:IMU) share price just hit an all-time high

The Imugene Limited (ASX: IMU) share price just hit an all-time high. Let’s take a look at the medical research company’s latest announcement.

| More on:
A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

The Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs.

At the time of writing, shares in the medical research and development company are up 11.5%, trading at a record high of 14.5 cents each. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.58% higher.

Today’s positive price movement comes as the company made a major announcement on its latest medical treatment.

Let’s delve deeper and see how it’s affecting the Imugene share price.

What’s pushing the Imugene share price higher?

In today’s ASX statement, Imugene advised that Phase I trials of its lung cancer vaccine, PD1-Vaxx, would “proceed to the third and final highest dose cohort”.

The company said an independent expert committee found the vaccine safe for humans at the mid-level dosage of 50 micrograms. The trial will now proceed to the full dosage of 100 micrograms.

According to the company, the results showed that one patient’s tumour almost completely disappeared after 6 weeks, while three others stabilised. One patient’s disease, however, did further progress. After 85 days, the status of two patients was unchanged.

Imugene says these early results are promising signs of the vaccine’s efficacy. The company also advised that the Mayo Clinic in Phoenix, Arizona, had received approval to join the Phase 1 clinical trial of PD1-Vaxx in the United States.

Stakeholder commentary

Principal investigator, Professor Gary Richards of Cabrini Hospital, Melbourne, said

I am excited to hear the Cohort Review Committee recommended opening the third and final dose cohort based on the outstanding safety and tolerability of PD1-Vaxx reviewed to date.

Imugene managing director and CEO Leslie Chong added:

Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial.

Imugene share price snapshot

Over the last 12 months, the Imugene share price increased by 625% and is now at an all-time high. In fact, in the past 6 months, the company’s share price value has increased by 141%.

At its current share price, Imugene has a market capitalisation of $676.8 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News